You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
上海医药(02607.HK)下属控股子公司脑血栓药物注射用尤瑞克林新纳入国家医保目录
格隆汇 11-29 18:35

格隆汇11月29日丨上海医药(02607.HK)公布,根据国家医疗保障局网站于2019年11月28日发布的《关于将2019年谈判药品纳入 <国家基本医疗保险、工伤保险和生育保险药品目录> 乙类范围的通知》(医保发【2019】65号),公司属控股子公司广东天普生化医药股份有限公司(以下简称"上药天普")的独家产品注射用尤瑞克林(商品名"凯力康")通过了医保谈判,首次被纳入《国家基本医疗保险、工伤保险和生育保险药品目录(2019年版)》(以下简称"《医保目录》")。

经统计,公司共有643个品种纳入本次《医保目录》,其中60个重点品种中已纳入《医保目录》的共计46个。

注射用尤瑞克林为上药天普独家生产的国家一类新药,2005年上市,先后被国家科技部列为"1035"工程、火炬计划、国家"十五"重大科技项目。该药通过独特的激肽释放酶-激肽系统,靶向开启脑缺血区侧支循环,快速改善脑血流灌注,适用于轻-中度急性血栓性脑梗死。目前,注射用尤瑞克林被我国五部权威脑卒中诊疗指南、一部指导规范、一部共识和两部教科书推荐,是临床不可或缺的一线治疗用药。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account